聯康生物科技(00690.HK)斥490萬人幣拓醫療美容材料業務
聯康生物科技(00690.HK)公布,旗下附屬Uni-Bioscience Pharm與集團主席梁國龍母親Judy Lau持有的寶萃訂立研發合作協議,以共同開發用於醫療美容用途之新項目材料,包括膠原蛋白、纖連蛋白等。
研發合作協議的期限為24個月期間,訂約方可於期限屆滿後2個月內再延長12個月,期限僅可延長一次。Uni-Bioscience Pharm預期為該項目提供資金約490萬元人民幣。根據研發合作協議,該項目可能產生或衍生的知識產權須由Uni-Bioscience Pharm及寶萃共同擁有。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.